Valproate vs levetiracetam in juvenile myoclonic epilepsy: systematic review and meta-analysis.
Lavínia Voss Agra, Marcela Caracas Machado Borges, Luiz Carlos Fonseca de Azevedo Oliveira et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and tolerability of valproate (VPA) versus levetiracetam (LEV) in juvenile myoclonic epilepsy (JME) patients. Analyzing seven studies with 1,009 patients, VPA showed higher seizure remission rates (344 of 574 vs. 169 of 390; RR 1.44, 95% CI 1.27-1.63) and lower treatment discontinuation rates compared to LEV, although substantial heterogeneity was noted.
Key findings
- VPA was associated with higher seizure remission rates compared to LEV (RR 1.44, 95% CI 1.27-1.63).
- VPA had a lower risk of drug failure or treatment discontinuation (RR 0.68, 95% CI 0.54-0.86).
- VPA was linked to a higher risk of memory impairment (RR 5.37, 95% CI 2.05-14.04).
- VPA also showed a higher risk of weight gain or obesity (RR 6.40, 95% CI 3.64-11.26).
Why it matters
Understanding the comparative efficacy and side effect profiles of VPA and LEV is crucial for clinicians managing JME, particularly given the chronic nature of the condition and the need for long-term treatment strategies.
What to keep in mind
Substantial heterogeneity and the predominance of observational studies limit the confidence in the findings.